Membership Home Portfolio Stocks Bonds Funds ETFs CEFs Markets Tools Real Life Finance Discuss
Home>Topics>>NPS Pharma Drifts Higher On Potential Orphan Drug Approval

NPS Pharma Drifts Higher On Potential Orphan Drug Approval

Long Investing Ideas from Seeking Alpha

Tue, 4 Dec 2012

By Brian L. Wilson : NPS Pharmaceuticals (NASDAQ: NPSP ) is one of the many biotech stocks that has given its shareholders exceptionally large returns this year. The Utah-based company has a diverse pipeline that contains five compounds, targeting four different indications. NPS' flagship product ...

Read the rest of this article on Long Investing Ideas from Seeking Alpha

Content Partners
Site Directory Site Map Our Products
Corrections Help Advertising Opportunities Licensing Opportunities Glossary RSS Mobile Portfolio Affiliate Careers Company News
International Sites: Australia Canada China France Germany Hong Kong Italy The Netherlands Norway Spain U.K. Switzerland India Finland
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.

© Copyright 2013 Morningstar, Inc. All rights reserved. Please read our Terms of Useand Privacy Policy.Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.